Background-We aimed to determine the prevalence of silent myocardial infarction (SMI) in people with newly diagnosed type 2 diabetes mellitus and its relationships to future myocardial infarction (MI) and all-cause mortality. Methods and Results-We examined data from the 5102 patients in the 30-year UK Prospective Diabetes Study (UKPDS) and used Cox proportional hazards regression to examine outcomes by SMI status. Of 1967 patients with complete baseline data, 326 (16.6%) had ECG evidence of SMI (Minnesota codes 1.1 or 1.2) at enrollment. Those with SMI were more likely to be older, female, sedentary, and nonsmokers compared with those without SMI. Their mean blood pressure was greater despite more intensive antihypertensive treatment; they were more likely to be taking aspirin and lipid-lowering therapy; and they had a greater prevalence of microangiopathy. Fully adjusted hazard ratios for those with versus those without SMI in multivariate models that included UKPDS Risk Engine variables were 1.58 (95% confidence interval, 1.22-2.05) for fatal MI and 1.31 (95% confidence interval,1.10-1.56) for all-cause mortality. Hazard ratios for first fatal or nonfatal MI and for first nonfatal MI were nonsignificant. The net reclassification index showed no improvement when SMI was added to these models, and the integrated discrimination index showed that SMI marginally improved the prediction of fatal MI and all-cause mortality. Conclusions-About 1 in 6 UKPDS patients with newly diagnosed type 2 diabetes mellitus had evidence of SMI, which was independently associated with an increased risk of fatal MI and all-cause mortality. However, identification of SMI does not add substantively to current UKPDS Risk Engine predictive variables. Clinical Trial Registration-URL: http://www.controlled-trials.com. Identifier: ISRCTN number 75451837. (Circulation. 2013;127:980-987.) The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/
A resting 12-lead ECG remains a simple and inexpensive component of recommended routine cardiovascular risk assessment in diabetes mellitus. 1 Silent myocardial infarction (SMI), defined as the presence of pathological Q waves in the absence of a history of typical cardiac symptoms, is one of the abnormalities that can be detected through ECG screening. Studies that have assessed prognosis in individuals with SMI from the general population have produced variable results. [2] [3] [4] [5] [6] Some have shown that mortality in those with SMI is higher than in those with a previous clinically evident myocardial infarction (MI). 6 However, other studies have revealed equivalent 4, 5 or even significantly lower 3 rates. There is some evidence that a relatively favorable outcome after SMI compared with clinical MI may be restricted to women. 2 
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There are few equivalent data from studies of patients with type 2 diabetes mellitus ( T2DM), but apparent inconsistencies have also emerged. In placebo-treated patients recruited to the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, those with SMI identified 2 years into follow-up had subsequent coronary heart disease (CHD) and all-cause mortality over the next 3 years similar to those who had suffered a clinical MI during the first 2 years on study. 7 In contrast, patients in the community-based observational Fremantle Diabetes Study (FDS) with SMI at study entry had significantly lower subsequent CHD and all-cause mortality over 7 years than patients with known CHD at baseline. 8 These discrepant results may reflect differences between the selected FIELD patient cohort and the more community-representative FDS patients such as in demographic characteristics, risk factor profiles, use of cardiovascular therapies, and duration of follow-up, as well as in categorization of patients and methods of analysis.
The UK Prospective Diabetes Study (UKPDS) 9 affords the opportunity to assess the prognostic importance of SMI in newly diagnosed T2DM patients without significant comorbidities who were followed up over a longer period than in other studies. We have examined the prevalence of SMI in UKPDS participants at enrollment, its correlates, and its relationship with subsequent clinically evident MI and death.
Methods

Patients
Full details of UKPDS participants have been published. 10 Briefly, 5102 of 7616 people referred by their general practitioners with newly diagnosed T2DM were enrolled. Exclusion criteria included severe vascular disease, MI or stroke within the previous year, and major systemic illness. The study received ethical committee approval in each of the 23 UK clinical centers and conformed to the Declaration of Helsinki guidelines. All patients gave informed consent before participation.
Study Design
The UKPDS protocol has been reported in detail. 9, 10 Briefly, enrolled patients underwent baseline assessment and then after a 3-to 4-month dietary run-in period before allocation to diet (if fasting plasma glucose <15 mmol/L), sulfonylurea, insulin, or, if >120% ideal body weight, metformin therapy. All patients were seen quarterly in UKPDS clinics for a median within-trial follow-up to the end of September 1997 of 10 years. The 3277 surviving patients then entered a 10 year posttrial monitoring period in a usual-care setting. 11 They were seen annually for 5 years in UKPDS clinics with 3-year clinical examinations and continued standardized collection of predefined outcomes and other data. In those unable to attend clinics and during years 6 to 10 to the end of September 2007 in all cases, these data were obtained from questionnaires sent to patients and their general practitioners. End-point adjudication for events, including fatal and nonfatal MI, was consistent throughout the intervention trial and the posttrial monitoring periods. 11 ECGs recorded throughout the study were coded by trained, independent observers using the Minnesota system. 12 SMI was defined as definite/probable Q-wave MI (Minnesota codes 1.1 and 1.2) without a history or typical symptoms of CHD (self-reported angina or MI, or symptoms interpreted as diagnostic by the attending clinician). Minor Q waves (Minnesota code 1.3) and left bundle-branch block (Minnesota code 7.1.1) were excluded because of their association with age and other nonischemic conditions. 13 ST-segment depression (Minnesota codes 4.1-4.3) and T-wave items (Minnesota codes 5.1-5.3) were excluded because of their nonspecific nature.
ECGs were recorded triennially, regardless of randomized therapy allocation, as part of the standardized comprehensive assessment of complications. Of the predefined UKPDS composite outcomes collected at or between assessments, 9,10 the definition of a clinically evident MI was based on World Health Organization clinical criteria in association with cardiac enzyme and ECG changes, including a new pathological Q wave. 9 SMIs were not included in this end point.
Statistical Analysis
Statistical analyses were performed with R (R Foundation for Statistical Computing, Vienna, Austria) and the survival package. Baseline characteristics were compared by use of the χ 2 test for categorical variables and the Wilcoxon rank-sum test for continuous variables. Survival analyses with time to first fatal or nonfatal MI, first nonfatal MI, and fatal MI (whether or not preceded by a nonfatal event) and all-cause mortality as dependent variables were performed with Cox proportional hazards regression models with forward stepwise selection of variables, including binary SMI status at baseline, that were independently associated with outcome at P<0.05. All clinically plausible variables were considered for model entry.
Multivariate modeling restricted to UKPDS Risk Engine variables for MI 14 was also performed. Interactions between variables were assessed by use of the likelihood ratio test. For the models based on the UKPDS Risk Engine, integrated discrimination improvement metrics were performed. 15 We also performed a net reclassification improvement assessment 15 to determine whether the presence or absence of SMI changed classification between CHD risk categories of 0% to <5%, 5% to <10%, 10% to <20%, and ≥20% using 5-year UKPDS Risk Engine estimates. 14
Results
Patients
Of the 5102 patients enrolled in the UKPDS, SMI status could not be ascertained in 86 patients (1.7%) who had missing ECG or clinical data. A further 189 patients (3.7%) were excluded because they had evidence of definite or possible CHD at the baseline assessment on clinical grounds, with or without ECG criteria. The remaining 4827 patients (94.6% of the total sample) could be assessed for SMI at entry, but those with other missing baseline data (mainly patients entering the UKPDS in the early years) were excluded from the final sample, specifically 972 (20.1%) without data on retinopathy, 728 (15.1%) without a serum high-density lipoprotein cholesterol concentration, 402 (8.3%) without a urinary creatinine concentration, 379 (7.9%) without a urinary albumin concentration, 157 (3.3%) with no hemoglobin A 1c , 122 (2.5%) with no data on neuropathy, 67 (1.4%) with no information on social class, 22 (0.5%) without a serum low-density lipoprotein cholesterol concentration, and 11 (0.2%) with ethnicity being other than white Caucasian, Afro-Caribbean, or Asian-Indian. Therefore, 1967 UKPDS patients (or 38.6% of the total UKPDS cohort) with complete baseline risk factor data were available for analysis.
SMI Prevalence and Correlates
The prevalence of SMI in the full cohort of 4827 increased progressively at each triennial assessment from 17.5% (845 patients) at baseline to 30.1% (680 of 2259 patients) at 12 years. The presence of Q waves was typically transient with, for example, 53% of those with SMI at baseline also having ECG evidence of an SMI at year 3.
The demographic, clinical, and biochemical characteristics of the 1967 patients with complete data at baseline are shown in Table 1 . Those with SMI were more likely to be older, female, and sedentary compared with those without SMI but less likely to be smokers. Their blood pressure was greater despite more intensive antihypertensive treatment; they were more likely to be taking aspirin and lipid-lowering therapy; and they had a greater prevalence of retinopathy and albuminuria at baseline. Table I in the online-only Data Supplement. SMI was associated with fatal MI and all-cause mortality with hazard ratios of 1.49 (95% confidence interval, 1.15-1.94) and 1.26 (95% confidence interval, 1.06-1.50), respectively, but not first fatal or nonfatal MI or first nonfatal MI. Female sex was protective for all outcomes, but when interactions between sex and SMI were included as separate terms in each model, none proved significant (P≥0.14 for all). There were no associations between randomly allocated study therapy and SMI for any outcome (data not shown).
Multivariable proportional hazards modeling was performed to evaluate whether SMI was associated with the outcomes of interest when added to those used by the UKPDS Risk Engine (Table 3 ). 14 SMI was significantly and independently associated with a 58% increased rate of fatal MI and a 31% increase in all-cause mortality, consistent with the analyses for all candidate associates summarized in Table I in the online-only Data Supplement. The results of net reclassification improvement analyses after risk classification, the integrated discrimination improvement, and the area under the receiver-operating characteristic curve for each end point are shown in Table 4 . Adding SMI to the risk engine model variables did not increase the area under the receiver-operating characteristic curve significantly. SMI did not change risk classification for any of the 4 end points (net reclassification improvement, all ≥−3.86%; P≥0.11 for all). The integrated discrimination improvement values suggested that, when risk was considered a continuous variable, addition of SMI marginally but significantly improved model performance (<1%) for both fatal MI (P=0.002) and all-cause mortality (P<0.001).
Discussion
This study shows that evidence of an SMI at the time of diagnosis of T2DM is significantly associated with a 58% increased rate of subsequent fatal MI and a 31% increased rate of all-cause mortality after adjustment for conventional cardiovascular risk factors. SMI at the diagnosis of T2DM, however, was not associated with a first nonfatal MI. Although SMI at diagnosis occurred more often in female patients, the SMI-associated increased rate of a subsequent fatal MI was independent of sex. Some modifiable cardiovascular risk factors, including hypertension and microalbuminuria, were more prevalent among patients with SMI. Nevertheless, when SMI was added to UKPDS Risk Engine variables in multivariate analyses, the improvement in prediction of key cardiovascular outcomes was marginal. The UKPDS was a primary cardiovascular prevention study of patients with newly diagnosed diabetes mellitus in that those with a history of MI in the previous 12 months and those with current angina or heart failure were excluded. 9 The most directly comparable data on SMI come from the communitybased observational FDS, in which SMI was defined as a definite or probable Q-wave MI on a Minnesota-coded baseline ECG without a history and/or typical symptoms of CHD. 8 Compared with those without SMI, FDS patients with SMI at baseline tended to be older, to more often be female, and to have higher blood pressure despite more intensive antihypertensive treatment, characteristics in common with these UKPDS patients with SMI. Other numeric differences between those with and without SMI in the FDS such as a greater prevalence of retinopathy and microalbuminuria in those with SMI were consistent with these UKPDS findings but were not statistically significant, probably because of the relatively small number of FDS patients with SMI (n=50). Systolic hypertension was a predictor of SMI in T2DM in the Rancho Bernardo Study 16 and in some population studies, 3, 17 but in contrast to both this study and the FDS, 8 smoking has been positively associated with SMI in the general population. 3, 18 In contrast to the significant associations in the present study, there were nonsignificant 74% and 9% increases in the rate of CHD death and all-cause mortality, respectively, associated with baseline SMI in the FDS. 8 This may also have reflected a lack of statistical power in the FDS. Alternatively, cardiac deaths in the FDS included those resulting from heart failure, 8 and this broader mortality category may have masked a between-group difference in fatal MI. In addition, use of antihypertensive, lipid-lowering, and aspirin therapy was significantly greater in the Australian FDS patients than in the UKPDS. 8 FDS recruitment was between 1993 and 1996, a time when the UKPDS trial period was drawing to a close and when evidence establishing the importance of multifaceted cardiovascular risk management was accumulating. Nevertheless, UKPDS and FDS data taken together suggest a consistent association between SMI in T2DM and an increased rate of subsequent cardiac and thus all-cause mortality compared with patients without CHD or SMI.
Table 2. Number of Patients With End Points, Absolute Risks, and Age-and Sex-Adjusted Hazard Ratios for Myocardial Infarction and All-Cause Mortality Outcomes in Patients Categorized by Silent Myocardial Infarction Status Using Data From the UKPDS (1977-2007)
Patients With End Points
In the FIELD study, an intervention trial in T2DM involving fenofibrate, almost one quarter of the patients had known cardiovascular disease at entry, but SMI status was ascertained only on ECGs taken at 2 years, at 5 years, and at study close-out. 7 Baseline risk factors were similar for patients with silent and clinical MI in FIELD, but characteristics of patients with SMI but no history of cardiovascular disease were not assessed. The 58 placebo-treated patients with SMI at 2 years had a prognosis over the next 3 to 4 years similar to that of the 79 patients who had experienced a clinical MI by 2 years, 7 but this may have been influenced by the at least one third with known cardiovascular disease.
SMI at baseline was not associated with a subsequent nonfatal MI in UKPDS patients, but there was a significant association with fatal MI. It is possible that patients with prior silent MI present relatively late because of attenuated symptoms. Effective coronary intervention is delayed as a result, and the risk of death increases. It is also possible that the association between SMI and microangiopathy, which can involve the myocardium, leads to a larger infarct size and subsequently increased risk of death in this group. 19 In addition, the presence of a prior Q-wave MI is itself a risk factor for death after acute MI. 20 The baseline prevalence of SMI in the UKPDS cohort was 17.5%, substantially higher than in more recent cross-sectional T2DM studies. In the FDS cohort, 4% of patients had SMI using Minnesota codes 1.1 and 1.2. 8 In FIELD, 1.3% of patients with an ECG assessment at 2 years had SMI. 7 In the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study, the prevalence of unrecognized Q-wave MI was 1.9% at baseline. 21 This inconsistency may be explained by different features of the patients in the UKPDS compared with the other studies and/or changes in CHD screening, diagnosis, and management over time. UKPDS patients were newly diagnosed, whereas the other 3 studies included patients with established diabetes mellitus. Prior screening for and detection of CHD might not have been as intensive in an individual not thought to have diabetes mellitus as a risk factor. In addition, the cardiovascular risk of patients referred from primary care for inclusion in the UKPDS may have been greater than that in patients not referred. Alternatively, the recent emergence of improved screening and diagnostic tests for CHD, 22 including biomarkers such as troponin, 23 as well as more effective coronary interventions, 24 may have meant that fewer Table 3 patients in FDS, FIELD, and RECORD had a first presentation with SMI compared with patients recruited to the UKPDS in the 1970s and 1980s. In the Rancho Bernardo Study, 16 18.7% of T2DM patients without a history or symptoms of CHD had an ECG abnormality. This included Minnesota codes 1.3, 4.1 to 4.4, 5.1 to 5.3, and 17.1.1, as well as 1.1 and 1.2 (both coronary probable and possible), but it is likely that there was a higher SMI prevalence (codes 1.1 and 1.2) than in FDS, FIELD, or RECORD. Given that Rancho Bernardo and UKPDS were conducted at about the same time, it could be that less intensive cardiovascular risk management before and after diagnosis of diabetes mellitus in the 1970s and 1980s increased the chance of SMI relative to later trials. In addition, because the UKPDS was the only study of SMI in diabetes mellitus to date that excluded patients with known cardiovascular disease, this may have increased the proportion with SMI relative to FDS, FIELD, RECORD, and Rancho Bernardo.
. Hazard Ratios From Multivariable Proportional Hazards Models Using Variables From the UKPDS Risk Engine and Presence or Absence of Silent Myocardial Infarction
The sensitivity and specificity of Q waves in the detection of MI have been questioned by several recent studies that have attempted to correlate their presence with evidence of cardiac muscle damage obtained with positron emission tomography, radionuclide scintigraphy, and cardiac magnetic resonance imaging, [25] [26] [27] including in T2DM. 28 The reason in part is that Q waves can resolve with time. 28, 29 The limitations of receiver-operating curve analysis are well recognized, 15, 30 but there were relatively small and nonsignificant increases in area under the receiver-operating characteristic curve (<0.01) when SMI was added to the predictive models that included UKPDS Risk Engine variables. In addition, there were no significant changes in categorization of risk by net reclassification improvement but marginal, albeit significant, improvements in risk prediction without categorization as assessed by integrated discrimination improvement when SMI was added to UKPDS Risk Engine variables for both fatal MI and all-cause mortality.
Overall, these results suggest that ECG Q waves in a previously asymptomatic patient with T2DM are of some prognostic significance, especially in relation to death. The debate concerning the adverse impact of intensive glycemic control on outcome notwithstanding, 31 the baseline associates of SMI in the present study, including hypertension and albuminuria, suggest that the presence of a silent MI on routine ECG screening should prompt review of the adequacy of management of modifiable cardiovascular risk factors in T2DM. In relation to cardiovascular risk prediction, the identification of SMI does not offer the same incremental predictive power as the UKPDS Risk Engine variables of age at diagnosis, sex, ethnicity, smoking, hemoglobin A 1c , systolic blood pressure, and ratio of total to high-density lipoprotein cholesterol. 14 
